Showing 14 RESULTS FOR
Migraine
Results from the DELIVER study with VYEPTI® (eptinezumab-jjmr) has been published in a top-ranking medical journal
News Releases
Results from the DELIVER study with VYEPTI® (eptinezumab-jjmr) has been published in a top-ranking medical journal
The primary and key secondary results on VYEPTI® (eptinezumab-jjmr) from the DELIVER study in patients with migraine and prior preventive treatment failures are now published in the high-impact medical journal Lancet Neurology.
Read Story
Lundbeck to Present New Data at AAN 2022 Adding to Clinical Evidence Regarding VYEPTI
News Releases
Lundbeck to Present New Data at AAN 2022 Adding to Clinical Evidence Regarding VYEPTI
Read Story
Lundbeck reports positive results for VYEPTI® (eptinezumab-jjmr) from the DELIVER study in patients with migraine and prior preventive treatment failures
News Releases
Lundbeck reports positive results for VYEPTI® (eptinezumab-jjmr) from the DELIVER study in patients with migraine and prior preventive treatment failures
Read Story
Dr. Roger Cady Recognized for Contribution to Migraine Medicine
Patient Voices
Dr. Roger Cady Recognized for Contribution to Migraine Medicine
Dr. Cady, a pioneer in migraine research, shares his hopes for the future of migraine care.
Read Story
Spotlight on Migraine Podcast: The Evolution of Migraine Disease
Science
Spotlight on Migraine Podcast: The Evolution of Migraine Disease
Dr. Roger Cady on why some people transition from episodic migraine to chronic migraine.
Read Story

This site contains medical information that is intended for residents of the United States only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site are subject to the terms and conditions as set out in our Privacy Policy and Terms of Use. 

© Copyright 2024 Lundbeck. All rights reserved.